Form 4: Allogene CTO Sells Shares for Tax Obligations

Allogene Therapeutics' SVP, Chief Technical Officer, Benjamin Beneski, sold 786 shares of common stock at a weighted average price of $1.22 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Benjamin Beneski, SVP, Chief Technical Officer of Allogene Therapeutics, Inc. (ALLO), sold 786 shares of common stock.
• The transaction occurred on November 17, 2025.
• The shares were sold at a weighted average price of $1.22, with prices ranging from $1.22 to $1.23.
• This sale was a "sell to cover" transaction, mandated by the company's equity incentive plan to satisfy tax withholding obligations upon the vesting of restricted stock units.
• The sale was not a discretionary trade by Mr. Beneski.
• Following the transaction, Mr. Beneski beneficially owns 217,721 shares of Allogene Therapeutics common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes related to RSU vesting. It is neutral in terms of company performance or management sentiment towards the stock.

Positives

• The underlying event is the vesting of restricted stock units, indicating compensation for the SVP, Chief Technical Officer.
• The transaction is non-discretionary, meaning it is a routine event for tax purposes rather than a signal of management selling off shares for other reasons.

Negatives

• No direct negatives from this specific transaction, as it is a routine tax-related sale.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all publicly traded companies when restricted stock units vest. It does not provide information relevant to broader industry trends or competitive landscape.

Comparison to Industry Standards

• This is a standard 'sell to cover' transaction for tax withholding, a common practice in equity compensation plans across various industries and companies of similar size and maturity to Allogene Therapeutics.
• For example, executives at biotech peers like Gilead Sciences or Amgen often engage in similar non-discretionary sales upon RSU vesting. The mechanism is a widely accepted method for managing tax liabilities associated with equity awards.

Related Party Transactions

• The transaction is a 'sell to cover' mandated by Allogene Therapeutics' equity incentive plan to satisfy tax withholding obligations. This is a standard, non-discretionary mechanism for managing executive compensation and tax liabilities, not a special related party dealing.

Stakeholder Impact

• Shareholders: Minimal direct impact as it is a routine, non-discretionary transaction for tax purposes. The underlying RSU vesting is a form of executive compensation.
• Employees: No direct impact on general employees.
• Customers, Suppliers, Creditors: No direct impact.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the reporting requirement itself.

Key Dates

Keywords

Allogene Therapeutics, ALLO, Form 4, Insider Transaction, Sell to Cover, Restricted Stock Units, Tax Withholding, Benjamin Beneski, SVP Chief Technical Officer